Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study [Phase 2]

View source ↗

Summary

Phase 2 trial exploring the addition of radium-223 dichloride to cabozantinib for advanced renal cell carcinoma with bone metastases (RadiCaL study).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Clear Cell Renal Cell Carcinoma
• Collecting Duct Carcinoma
• Kidney Medullary Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING